<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534079</url>
  </required_header>
  <id_info>
    <org_study_id>pulmozyme-nasal-cf</org_study_id>
    <nct_id>NCT00534079</nct_id>
  </id_info>
  <brief_title>Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis</brief_title>
  <official_title>Nasal Inhalation of Dornase Alfa (Pulmozyme) in Patients With Cystic Fibrosis and Chronic Rhinosinusitis - a Double Blind Placebo-controlled Cross-over, Bicenter, Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality&#xD;
      of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a&#xD;
      dysfunction of chloride channels in exocrine glands, leading to retention of secretions and&#xD;
      consecutive chronic inflammation with bacterial superinfections.&#xD;
&#xD;
      The prospective placebo controlled cross-over study aims at the evaluation of a nasally&#xD;
      inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (primary nasal parameters: obstruction of nasal breathing, sneeze stimulus, permanent nose running, thick-mucous nasal discharge, earaches)</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (secondary nasal parameters, general quality of live parameters and total SNOT 20 adapt. CF score)</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of pathological alterations visible in MRT images of nose and paranasal sinuses (in selected patients)</measure>
    <time_frame>day 1, 29, 57, 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the nasal lavage fluid and in the serological markers of inflammation</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinoscopic findings</measure>
    <time_frame>day 1, 29, 57 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in rhinomanometric findings</measure>
    <time_frame>day 1, 29, 27 and 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of rhinosinusitic and pulmonary exacerbations during therapy</measure>
    <time_frame>day 1 - 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for decongestants or nasal lavage during treatment</measure>
    <time_frame>day 1 - 85</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 days of sinonasal inhalation (Pari Sinus)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isotonic saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>28 days of sinonasal inhalation (Pari Sinus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dornase alfa (Pulmozyme)</intervention_name>
    <description>1 x 2,5 ml per day, inhalation use, for 28 days</description>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotonic saline</intervention_name>
    <description>1 x 2,5 ml per day, inhalation use, for 28 days</description>
    <arm_group_label>Dornase alfa</arm_group_label>
    <arm_group_label>isotonic saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a confirmed diagnosis of cystic fibrosis based on: 3 positive sweat&#xD;
             chloride tests and/or genetic characterisation&#xD;
&#xD;
          -  Subject is 5 years of age or older&#xD;
&#xD;
          -  Subject has chronic or recurrent rhinosinusitic disorders&#xD;
&#xD;
          -  Subject is able to comply with the procedures scheduled in the protocol&#xD;
&#xD;
          -  Women of childbearing potential are only included into the study, if they are using an&#xD;
             effective method of birth control during the protocol (e.g. implants, combined oral&#xD;
             contraceptives, injectables, some IUDs, sexual abstinence or vasectomised partner)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a critical condition defined as: FEV1 &lt; 30% and / or SaO2 &lt; 93% without&#xD;
             O2-substitution; need of O2-substitution&#xD;
&#xD;
          -  Subject had an ENT surgery within 6 months prior to study&#xD;
&#xD;
          -  Subject shows signs of nasal bleeding&#xD;
&#xD;
          -  Subject has an ear drum perforation&#xD;
&#xD;
          -  Subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with&#xD;
             need of additional systemic antibiotic therapy&#xD;
&#xD;
          -  Subject has a new therapy with nasal topic steroids during treatment interval&#xD;
&#xD;
          -  Subject has a new systemic steroid therapy&#xD;
&#xD;
          -  Subject is unlikely to comply with the procedures scheduled in the protocol&#xD;
&#xD;
          -  Subject has a known allergic reaction to the medication&#xD;
&#xD;
          -  Subject is pregnant or breastfeeding&#xD;
&#xD;
          -  Patient participates in another clinical trial within 30 days prior to study entry or&#xD;
             30 days after end of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochen Mainz, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Jena</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Würtemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mukoviszidosezentrum der Friedrich-Schiller-Universität</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mainz JG, Michl R, Arnold C. Response to Karadag. J Cyst Fibros. 2014 Sep;13(5):602-3. doi: 10.1016/j.jcf.2014.07.005. Epub 2014 Jul 28.</citation>
    <PMID>25081561</PMID>
  </reference>
  <results_reference>
    <citation>Mainz JG, Schien C, Schiller I, Schädlich K, Koitschev A, Koitschev C, Riethmüller J, Graepler-Mainka U, Wiedemann B, Beck JF. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial. J Cyst Fibros. 2014 Jul;13(4):461-70. doi: 10.1016/j.jcf.2014.02.005. Epub 2014 Mar 1.</citation>
    <PMID>24594542</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>September 21, 2007</study_first_submitted>
  <study_first_submitted_qc>September 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Jena</investigator_affiliation>
    <investigator_full_name>PD Dr. Jochen G. Mainz</investigator_full_name>
    <investigator_title>Head of CF Center</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis and chronic rhinosinusitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

